Prevents malaria. ANDA 211584, held by Ajanta Pharma Ltd. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 211584 (Doxycycline Hyclate), held by Ajanta Pharma Ltd, was first approved by FDA on Jun 1, 2020, with 0 approved supplements and 0 published complete response letters.
Doxycycline hyclate is a tetracycline class drug indicated for: Rickettsial infections Sexually transmitted infections Respiratory tract infections Specific bacterial infections Ophthalmic infections Anthrax, including inhalational anthrax (post-exposure) Alternative treatment for selected infections when penicillin is contraindicated Adjunctive therapy for acute intestinal amebiasis and severe acne Prophylaxis of malaria To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be cause…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 1, 2020 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 75MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 150MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters